Modelling drug responses and evolutionary dynamics using triple negative breast cancer patient-derived xenografts
A. Shea, Y. Eyal-Lubling, D. Guerrero-Romero, R. Manzano Garcia, W. Greenwood, M. O'Reilly, D. Georgopoulou, M. Callari, G. Lerda, S. Wix, A. Giovannetti, R. Masina, E. Esmaeilishirazifard, A. G. Martin, A. Nagano, , A. Bruna
This paper uses TNBC patient-derived xenografts to model drug responses and evolutionary dynamics, revealing a novel mechanism of olaparib response and synergistic effects with salinomycin.
bioRxiv · Jan 10, 2023 · PreprintCancer Biology